IP Library Granted Patent US 11,186,864
Granted Patent B2
US 11,186,864 · App. 16/417,071 · Granted Nov 30, 2021

Nicking and extension amplification reaction (near) of

Inventors: Daiwei Shen (San Diego, CA); Richard Roth (Carlsbad, CA); Honghua Zhang (San Diego, CA)
Assignee: IONIAN TECHNOLOGIES, LLC
C12Q1/6844C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,186,864
App. No.
16/417,071
Granted
Nov 30, 2021
Kind
B2
Abstract

This invention relates to compositions, methods and kits for detecting the presence or absence of a bacterial species in a biological sample using isothermal nucleic acid amplification.

Claims (33)

1. A composition comprising:

i) a forward template comprising a nucleic acid sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of the Streptococcus pyogenes ( S. pyogenes ) cell envelope proteinase A (cepA) gene antisense strand; a nicking enzyme binding site and a nicking site upstream of said recognition region; and a stabilizing region upstream of said nicking site;

ii) a reverse template comprising a nucleotide sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of the S. pyogenes cepA gene sense strand; a nicking enzyme binding site and a nicking site upstream of said recognition region; and a stabilizing region upstream of said nicking site; and

iii) a probe oligonucleotide comprising a nucleotide sequence having at least 80, 85, or 95% identity to SEQ ID NO: 3

(ACAAGTATGTGAGGAGAGGCCATACTTGT).

2. The composition of claim 1 further comprising a probe oligonucleotide comprising a sequence complementary to the S. pyogenes cell envelope proteinase A (cepA) nucleotide sequence.

3. The composition of claim 2 wherein said probe oligonucleotide comprising a sequence complementary to the S. pyogenes cell envelope proteinase A (cepA) nucleotide sequence is conjugated to a detectable label.

4. The composition of claim 3 wherein the detectable label is selected from the group consisting of a fluorophore, an enzyme, a quencher, an enzyme inhibitor, a radioactive label, a member of a binding pair, and a combination thereof.

5. The composition of claim 1 wherein the portion of the nucleic acid sequence that is complementary to the 3′ end of the target antisense strand is 8-30 nucleotides in length.

6. The composition of claim 1 wherein the portion of the nucleic acid sequence that is complementary to the 3′ end of the target sense strand is 8-30 nucleotides in length.

7. The composition of claim 1 further comprising one or more of; a) a DNA polymerase; b) one or more nicking enzymes; and c) dNTPs or a mixture of dNTPs and ddNTPs.

8. The composition of claim 7 wherein the DNA polymerase is selected from the group consisting of Geobacillus bogazici DNA polymerase, Bst (large fragment), and exo-DNA Polymerase.

9. The composition of claim 7 wherein the one or more nicking enzymes is/are selected from the group consisting of Nt.BspQI, Nb.BbvCi, Nb.BsmI, Nb.BsrDI, Nb.BtsI, Nt.AlwI, Nt.BbvCI, Nt.BstNBI, Nt.CviPII, Nb.Bpu10I, Nt.Bpu10I, and N.BspD61.

10. The composition of claim 1 further comprising a lytic agent.

11. The composition of claim 10 wherein the lytic agent comprises a bacteriophage lysin.

12. The composition of claim 11 wherein the bacteriophage lysin comprises streptococcal C1 bacteriophase lysin (PlyC).

13. The composition of claim 1 wherein the composition is lyophilized.

14. The composition of claim 1 wherein the forward template and/or the reverse template comprises one or more modified nucleotides, spacers, or blocking groups.

15. The composition of claim 14 wherein at least one modified nucleotide includes a 2′ modification.

16. The composition of claim 15 wherein at least one modified nucleotide includes a 2′-O-methyl.

17. The composition of claim 14 wherein the forward template and/or the reverse template comprises at least one phosphorothioate.

18. A kit comprising:

i) a forward template comprising a nucleic acid sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of the Streptococcus pyogenes ( S. pyogenes ) cell envelope proteinase A (cepA) gene antisense strand; a nicking enzyme binding site and a nicking site upstream of said recognition region; and a stabilizing region upstream of said nicking site;

ii) a reverse template comprising a nucleotide sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of the S. pyogenes cepA gene sense strand; a nicking enzyme binding site and a nicking site upstream of said recognition region; and a stabilizing region upstream of said nicking site; and

iii) a probe oligonucleotide comprising a nucleotide sequence having at least 80, 85, or 95% identity to SEQ ID NO: 3

(ACAAGTATGTGAGGAGAGGCCATACTTGT).

19. The kit of claim 18 further comprising a swab.

20. The kit of claim 18 further comprising a lytic agent and one or more of; 1) dNTPs; or 2) a mixture of dNTPs and ddNTPs.

21. The kit of claim 18 optionally comprising reagent for extracting and/or isolating nucleic acid from a biological sample.

22. The kit of claim 18 wherein the template oligonucleotide comprises one or more modified nucleotides, spacers, or blocking groups.

23. The kit of claim 22 wherein at least one modified nucleotide includes a 2′ modification.

24. The kit of claim 23 wherein at least one modified nucleotide includes a 2′-O-methyl.

25. The kit of claim 18 further comprising a polymerase.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTACHED DOCUMENT PREVIOUSLY RECORDED AT REEL: 052673 FRAME: 0682. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 6, 2022
From: ALERE HEALTH IMPROVEMENT COMPANY
To: NEWCO RD, LLC
Reel/Frame 058565/0833 →
MERGER Recorded May 15, 2020
From: IONIAN TECHNOLOGIES INC.
To: ALERE HEALTH IMPROVEMENT COMPANY
Reel/Frame 052673/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2020
From: ALERE HEALTH IMPROVEMENT COMPANY
To: NEWCO RD, LLC
Reel/Frame 052673/0682 →
CHANGE OF NAME Recorded May 15, 2020
From: NEWCO RD, LLC
To: IONIAN TECHNOLOGIES, LLC
Reel/Frame 052679/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2019
From: SHEN, DAIWEI; ROTH, RICHARD; ZHANG, HONGHUA
To: IONIAN TECHNOLOGIES, INC.
Reel/Frame 051063/0535 →